A Phase I study of a novel murine stem cell virus CD19/CD22-4-1BB bivalent CAR T-cell product showed a CR rate of 60% among twenty children and young adults with R/R B-ALL (NCT03448393). The gene discussed is CD22; the disease is acute lymphoblastic leukemia.